ARCHIVES

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

Also Von Eschenbach role in industry program raises new concerns of conflict of interest.

November 23, 2005

IL13-PE38 Looks Promising In Early Tests Against Gioma

September 27, 2002

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

October 31, 2014

Hammer Says He’ll Demand Construction Funds If Data Supports The Need

August 12, 1983

Guest Editorial: Gerard Silvestri calls for uniform guideline for CT screening for lung cancer

July 1, 2011

AIDS Research Loan Repayment Program

January 10, 1992